Summary
50 / 100 · Bulios Score
What speaks for it
- Revenue grew by 367% a year over the last 3 years.
- Analysts expect revenue to grow by 43% this fiscal year.
What to watch
- The share price is above the Bulios Fair Price.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 127.0 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 367% a year over the last 3 years. For the next fiscal year analysts expect revenue to grow by 43%.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 8.9 USD
- Research and development 20 USD
- Sales and administration 64 USD
- Taxes and other 1.2 USD
- Net profit 6.1 USD
Net profit, industry median (Biotechnology) -7.1 USD
Out of every 100 USD of revenue, 6.1 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.9 years of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 10
- Hold 2
- Sell 0
Today's price within the analysts' price targets
The average target of $38 is 32% above today's price. 83% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2023By product
- Other Revenue 51%
- Product 49%
By region
The company reports no revenue by region.
Other Revenue brings in 51% of revenue.
Segments in detail